01Role and principlesWho benefits and the main preventive aims.
A diagnosis of lower-limb PAD identifies established atherosclerotic cardiovascular disease. The leg may remain stable while the patient experiences myocardial infarction, stroke or vascular death, so prevention is a core PAD treatment rather than an optional addition to symptom care. Discuss absolute benefit, bleeding and medicine burden in terms the patient can use, then document who will monitor each intervention.
A practical plan combines smoking cessation, lipid lowering, antithrombotic treatment, blood-pressure management, diabetes care, exercise, diet and attention to kidney disease. National NICE recommendations define lipid and selected antithrombotic options; local formularies determine product selection and shared-care arrangements. Coexisting atrial fibrillation, recent coronary intervention, stroke, renal impairment or bleeding can change the regimen and should trigger deliberate reconciliation rather than automatic stacking of medicines.
Key points
- PAD is established cardiovascular disease even when leg symptoms seem mild.
- Offer intensive lipid lowering; NICE starts secondary prevention with atorvastatin 80 mg daily.
- Choose antiplatelet or intensified antithrombotic therapy from indication and bleeding risk.
- Smoking treatment, blood-pressure control, diabetes care and physical activity all matter.
- Review adherence and adverse effects before labelling preventive treatment ineffective.
- Check lipids and liver transaminases after starting or changing statin therapy.
- Coordinate coronary, cerebrovascular and limb indications to avoid duplicate antithrombotic treatment.
- Continue foot surveillance and urgent safety-netting while reducing systemic risk.
02Assessment and patient selectionRisk features, eligibility and important cautions.
Symptomatic PAD, previous lower-limb revascularisation or objective arterial disease places the patient in a secondary-prevention population regardless of a calculated primary-risk score.
Ask about angina, myocardial infarction, TIA or stroke, carotid disease and prior arterial procedures because multiple territories increase ischaemic risk and complicate antithrombotic choice.
Previous gastrointestinal or intracranial bleeding, anaemia, frailty, falls, kidney or liver disease, alcohol excess and interacting medicines alter antithrombotic net benefit.
Distinguish true adverse effects from non-adherence, access barriers or misconceptions, checking timing, interactions and rechallenge options before abandoning effective prevention.
New chest pain, focal neurological deficit or sudden painful cold limb is an emergency and must not wait for routine risk-factor review.
New rest pain, ulceration or gangrene warrants urgent vascular assessment even while cardiovascular preventive treatment continues.
03Baseline assessmentMeasurements that guide the plan and track progress.
Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.
- 01
Baseline lipid profile and liver transaminasesFirst step - Why
- Quantify atherogenic cholesterol and establish safety information before intensive lipid lowering.
- Interpretation and limitations
- Use total, HDL, non-HDL and LDL cholesterol to establish a baseline and assess response. Mild stable transaminase elevation below three times the upper limit of normal does not automatically preclude statin treatment under NICE guidance; investigate clinically significant abnormalities.
- 02
Repeat lipid profile and liver transaminases - Why
- Confirm response, adherence and early hepatic tolerance after treatment changes.
- Interpretation and limitations
- NICE recommends lipids and transaminases at two to three months after starting or changing lipid treatment. Recheck transaminases at twelve months, then only if clinically indicated; failure to reach target should prompt adherence, dose and add-on review.
- 03
Blood pressure including postural assessment when indicated - Why
- Detect and safely treat hypertension without overlooking orthostatic symptoms or frailty.
- Interpretation and limitations
- Confirm persistent hypertension with the recommended clinic and out-of-office pathway where appropriate. Apply current NICE targets to age, comorbidity and standing pressure; PAD does not justify ignoring symptomatic hypotension.
- 04
HbA1c or glucose and renal function - Why
- Identify diabetes control and renal constraints relevant to vascular risk and prescribing.
- Interpretation and limitations
- Interpret against the individual diabetes plan and eGFR trend. Kidney impairment increases both vascular and bleeding risk and may alter medicine eligibility, monitoring and dose, but does not remove the need for prevention.
- 05
Full blood count and bleeding review - Why
- Establish haemoglobin and platelet context before or during antithrombotic treatment.
- Interpretation and limitations
- Unexplained anaemia, thrombocytopenia or falling haemoglobin requires evaluation rather than reflex continuation or permanent cessation. Relate results to symptoms, renal function, medicines and the urgency of the vascular indication.
04InterventionsLifestyle, treatment and escalation options.
01Initial prevention planBuild one coordinated vascular-risk prescriptionFirst stepPAD is diagnosed or a patient with established PAD enters ongoing care.+
- 1Confirm smoking, blood pressure, lipids, diabetes, renal function, diet, physical activity, bleeding history and all cardiovascular diagnoses and procedures.
- 2Offer intensive statin treatment and select antiplatelet therapy according to NICE indications, contraindications, current anticoagulation and recent coronary or cerebrovascular treatment.
- 3Provide behavioural and pharmacological smoking support, agree exercise and dietary actions, and manage hypertension and diabetes through the applicable national pathways.
- 4Record baseline results, patient priorities, medicine cautions, monitoring dates and which clinician or service owns follow-up.
- 5Explain urgent symptoms of myocardial infarction, stroke, acute limb ischaemia and chronic limb threat alongside medicine-specific bleeding safety advice.
02Lipid reviewReach the secondary-prevention lipid target safelyTwo to three month results remain above target or the patient reports adverse effects.+
- 1Check adherence, administration, diet, alcohol, interacting drugs, thyroid or other secondary causes and whether symptoms truly track statin exposure.
- 2AlternativeMaximise tolerated statin intensity, using a lower dose or alternative statin when adverse-effect risk, interaction or preference prevents atorvastatin 80 mg.
- 3For secondary prevention, aim for LDL cholesterol at or below 2.0 mmol/L or non-HDL cholesterol at or below 2.6 mmol/L under current NICE guidance.
- 4Consider ezetimibe and later NICE-approved agents according to the treatment pathway and eligibility, with appropriate specialist or local formulary arrangements.
03Antithrombotic reviewBalance ischaemia against bleedingA vascular diagnosis, bleeding event, anticoagulation indication or coronary procedure changes the risk balance.+
- 1List the exact indication and planned duration for every antiplatelet and anticoagulant rather than inheriting an unexplained combination.
- 2Assess bleeding history, haemoglobin, kidney and liver function, falls, gastroprotection need and interacting anti-inflammatory or antithrombotic medicines.
- 3Use NICE technology-appraisal eligibility for any rivaroxaban-plus-aspirin vascular regimen and involve the relevant specialist when indications compete.
- 4Document the chosen regimen, review or stop point and advice for bleeding, procedures and missed doses.
04Smoking treatmentTurn advice into an assisted quit attemptThe patient currently smokes or has recently stopped and wants relapse-prevention support.+
- 1Ask about dependence, previous attempts, triggers, preferences, mental health, pregnancy potential and current medicines.
- 2Offer behavioural support with a licensed stop-smoking medicine suited to the person and the current NICE tobacco guideline.
- 3Arrange early follow-up to manage adverse effects, lapses and adherence, treating a lapse as information for the next attempt rather than failure.
05Medicines and treatment safetyRegimens, contraindications and review points.
Atorvastatin
Offer 80 mg orally once daily for secondary prevention; use a lower dose when interactions, adverse-effect risk or patient preference require it.Check baseline lipids and liver transaminases, pregnancy status where relevant, interacting medicines and unexplained muscle symptoms. Review two to three months after starting or changing treatment. The NICE page records that this recommendation involved off-label use in December 2023, so confirm current product authorisation when prescribing.
Clopidogrel (Milpharm 75 mg tablets)
75 mg orally once daily when selected for long-term prevention of occlusive vascular events in PAD.Do not use in active pathological bleeding or severe hepatic impairment. Review anaemia, bleeding history, other antithrombotics and procedure plans. Concomitant omeprazole or esomeprazole is discouraged because reduced CYP2C19 activation can weaken the antiplatelet effect.
Ezetimibe (Ezetrol 10 mg tablets)
10 mg orally once daily, alone when statins are contraindicated or not tolerated, or added to maximally tolerated statin treatment.Ezetrol is not recommended in moderate or severe hepatic impairment. Monotherapy should be used during pregnancy only if clearly necessary and must not be used during breastfeeding. Statin combination is contraindicated during pregnancy, breastfeeding, active liver disease or persistent unexplained transaminase elevation. Check liver tests with a statin, assess new muscle symptoms promptly, and review ciclosporin and warfarin interactions.
06Targets, monitoring and follow-upResponse, safety and longer-term review.
- Repeat full lipid profile and liver transaminases two to three months after starting or changing lipid-lowering treatment.
- Check liver transaminases again at twelve months after statin initiation, then only when clinically indicated.
- Review blood pressure, smoking, diabetes control, kidney function, physical activity and adherence at planned vascular or primary-care reviews.
- Ask directly about bruising, gastrointestinal bleeding, neurological symptoms, muscle symptoms and every non-prescription anti-inflammatory medicine.
- Reconcile antiplatelets and anticoagulants after hospital discharge, coronary intervention, stroke, bleeding or a planned invasive procedure.
- Monitor feet and walking symptoms, because systemic risk reduction does not replace urgent assessment of new limb threat.
07Special situationsVariants, exceptions and circumstances that change the usual approach.
Primary-risk calculators are unnecessary
Once PAD is established, the patient already has clinical cardiovascular disease; treatment should not be withheld because a primary-prevention risk score appears modest.
Target and intensity are linked
NICE begins secondary prevention with atorvastatin 80 mg and also uses an LDL or non-HDL target to trigger adherence, dose and add-on review.
More antithrombotic is not automatically better
Atrial fibrillation, recent stenting and polyvascular disease create competing indications, while duplicate therapy can sharply increase bleeding; name each indication and duration.
Rivaroxaban has restricted eligibility
NICE TA607 permits rivaroxaban plus aspirin within its marketing authorisation for selected high-risk coronary or symptomatic peripheral artery disease after bleeding-risk assessment; it is not routine for every PAD patient.
Limb and life outcomes coexist
Walking therapy and revascularisation address function and limb events, while lipid, antithrombotic and smoking treatment primarily reduce systemic vascular harm; both plans are needed.
08Common pitfallsFrequent interpretation and management errors.
- 01
Using a primary-prevention calculator to decide whether a person with established PAD deserves secondary prevention.
- 02
Prescribing multiple antiplatelet or anticoagulant medicines without a named indication, duration and bleeding review.
- 03
Stopping statin therapy permanently after nonspecific symptoms without checking interactions, alternatives or tolerated dosing.
- 04
Giving brief smoking advice without behavioural support, pharmacotherapy discussion or arranged follow-up.
- 05
Treating a satisfactory ABPI or walking distance as evidence that myocardial infarction and stroke risk is low.
- 06
Allowing routine prevention review to delay emergency assessment of chest pain, focal deficit or acute limb ischaemia.